USPTO 2015–2025 USPTO PatentsView US Corporation

Genentech, Inc.

USPTO PatentsView assignee record — 1,039 granted patents across 46 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

1,039
Total patents granted
46
CPC technology areas
23.2
Avg claims per patent
+4%
5-year filing velocity

Portfolio overview

Genentech, Inc. has been granted 1,039 US utility patents between 2015 and 2025, placing Genentech, Inc. at rank #437 across all assignees tracked by PlainPatent. This portfolio spans 46 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Genentech, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 66.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 529 grants, compared with 510 in the 2015–2019 window — a +4% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Genentech, Inc.'s 23.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 46 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Genentech, Inc. against peers pursuing similar technology classes.

How does Genentech compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Genentech holds 1,039 patents — placing it at rank #437 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

6080100120140 20152016201720182019202020212022202320242025 80
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Genentech, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 82 7.9%
2016 93 9.0%
2017 104 10.0%
2018 129 12.4%
2019 102 9.8%
2020 113 10.9%
2021 107 10.3%
2022 66 6.4%
2023 77 7.4%
2024 86 8.3%
2025 80 7.7%

Which technologies does Genentech, Inc. patent most?

Top 15 of 46 technology areas

Patent Moat Analysis

Portfolio Volume Strong
Tech Breadth Multi-domain
Claim Depth Complex
Velocity Growing

Where it ranks

Overall rank by patents

#437

Across all tracked assignees

Innovation Score

66.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Genentech, Inc. hold?
Genentech, Inc. holds 1,039 US granted patents filed between 2015 and 2025, spanning 46 technology areas.
What is Genentech, Inc.'s Innovation Score?
Genentech, Inc. has an Innovation Score of 66.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Genentech, Inc. focus on?
Genentech, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 789 patents. The company has filed patents in 46 CPC subclasses total.
Is Genentech, Inc.'s patent filing rate increasing or decreasing?
Genentech, Inc.'s recent filing velocity is +4% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Genentech, Inc.'s patents?
Genentech, Inc.'s patents average 23.2 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Genentech, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope